Hepatitis C Virus | Current Treatment | US | 2016
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common indication for liver transplantation. The 2013-2015 FDA approvals of Gilead’s Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir) combined with Bristol Myers Sqibb’s Daklinza (daclatasvir) and AbbVie’s Viekira Pak (ombitasvir/paritaprevir/ritonavir + dasabuvir) has ushered in the era of IFN-free therapy for chronic HCV infections and have completely reshaped the HCV therapeutic market. Recent approval of Merck’s Zepatier (elbasvir/grazoprevir) has provided an additional interferon-free option for genotype 1 and 4 patients. Taken together, currently approved regimens provide efficacious interferon-free options for most HCV genotypes. This research focuses on current and anticipated use of all-oral HCV regimens, including IFN-free and remaining IFN-based regimens, by capturing patient market share data, current prescribing trends and anticipated changes in prescribing and treatment behavior. For key brands, physician perceived drivers and limitations to prescribing behavior, and sales force performance will be evaluated.
